Each mL contains Tirofiban Hydrochloride Monohydrate-0.281mg (as Tirofiban
AGGRASTAT, in combination with heparin,
is indicated for the treatment of acute coronary syndrome, including patients
who are to be managed medically and those undergoing percutaneous transluminal
coronary angioplasty (PTCA) or atherectomy. In this setting, AGGRASTAT has been
shown to decrease the rate of a combined endpoint of death, new myocardial
infarction or refractory ischemia/repeat cardiac procedure.